

Retraction

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

Holbrook E. Kohrt, Roch Houot, Kipp Weiskopf, Matthew J. Goldstein, Ferenc Scheeren, Debra Czerwinski, A. Dimitrios Colevas, Wen-Kai Weng, Michael F. Clarke, Robert W. Carlson, Frank E. Stockdale, Joseph A. Mollick, Lieping Chen, and Ronald Levy

Original citation: *J Clin Invest.* 2012;122(3):1066–1075. <https://doi.org/10.1172/JCI61226>.

Citation for this retraction: *J Clin Invest.* 2019;129(6):2595. <https://doi.org/10.1172/JCI129688>.

Stanford University School of Medicine recently notified the *JCI* of concerns regarding Figure 4, A and C, and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the *JCI* is retracting this article.

Retraction

Targeting CD137 enhances the efficacy of cetuximab

Holbrook E. Kohrt, A. Dimitrios Colevas, Roch Houot, Kipp Weiskopf, Matthew J. Goldstein, Peder Lund, Antonia Mueller, Idit Sagiv-Barfi, Aurelien Marabelle, Ruth Lira, Emily Troutner, Lori Richards, Amanda Rajapaska, Jonathan Hebb, Cariad Chester, Erin Waller, Anton Ostashko, Wen-Kai Weng, Lieping Chen, Debra Czerwinski, Yang-Xin Fu, John Sunwoo, and Ronald Levy

Original citation: *J Clin Invest.* 2014;124(6):2668–2682. <https://doi.org/10.1172/JCI73014>.

Citation for this retraction: *J Clin Invest.* 2019;129(6):2595. <https://doi.org/10.1172/JCI129689>.

Stanford University School of Medicine recently notified the *JCI* of concerns regarding Figure 4, B, C, and E, Figure 5, B, D, and F, and Figure 6B and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the *JCI* is retracting this article.